CIGB 370

Drug Profile

CIGB 370

Alternative Names: CIGB-370

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Antineoplastics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Feb 2016 Preclinical trials in Cancer in Cuba (IV) before February 2016 (RPCEC00000209)
  • 01 Feb 2016 Center for Genetic Engineering and Biotechnology plans a phase I trial for Cancer (Metastatic disease) in Cuba (RPCEC00000209)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top